Bruker Corporation (BKD.F)
| Previous Close | 68.06 |
| Open | 70.46 |
| Bid | 70.08 x 60000 |
| Ask | 70.52 x 60000 |
| Day's Range | 70.46 - 70.46 |
| 52 Week Range | 51.50 - 86.50 |
| Volume | |
| Avg. Volume | 59 |
| Market Cap | 10.674B |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | 27.74 |
| EPS (TTM) | 2.54 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | 0.18 (0.27%) |
| Ex-Dividend Date | Feb 29, 2024 |
| 1y Target Est | 84.36 |
Business WireBruker Corporation to Host Investor Webinar on May 17, 2024
BILLERICA, Mass., May 09, 2024--Bruker Corporation (Nasdaq: BRKR) today announced it intends to hold an Investor Webinar from 10 am to about 12 noon Eastern Daylight Time (EDT) on May 17, 2024, to provide additional insights into its three recent acquisitions of Chemspeed, ELITech, and of the NanoString business. Bruker also expects to provide an update to its medium-term financial outlook.
- GuruFocus.com
Accelerate Diagnostics Inc (AXDX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Despite a slight revenue increase and reduced operational costs, AXDX faces a growing net loss and strategic hurdles in advancing its WAVE system.
Business WireGerman Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win to NanoString and Bruker
BILLERICA, Mass., May 07, 2024--Bruker Corporation (Nasdaq: BRKR) today announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European Patent No. 2794928B1 (the "928 Patent") in Germany (case 3 Ni 20/22). NanoString is now a Bruker business following Bruker’s asset acquisition of the businesses of NanoString Technologies, Inc on May 6th, 2024. The 928 Patent has been asserted by 10x Genomics against NanoString in patent infringe
